Pasithea Therapeutics Activates Clinical Trial Sites in South Korea for NF1 Study

Pasithea Therapeutics Corp. announced the activation of two clinical trial sites in South Korea for its Phase 1/1b open-label study of PAS-004 in adult patients with neurofibromatosis type 1 (NF1). The sites, Asan Medical Centre and Severance Hospital Yonsei University Health System, are now actively recruiting participants, with the first patient in South Korea already dosed. The study aims to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PAS-004, a next-generation macrocyclic MEK inhibitor. Initial interim clinical data from the first two cohorts is expected in the first quarter of 2026. The trial is part of Pasithea's broader efforts to develop treatments for RASopathies, MAPK pathway-driven tumors, and other diseases.